In vivo residence duration of human growth hormone loaded in nanogels comprising cinnamoyl alginate, cinnamoyl Pluronic F127 and cinnamoyl poly(ethylene glycol)

Daily subcutaneous injection of human growth hormone has been used for the treatment of growth hormone deficiency and growth failure but has led to poor patient compliance and renal toxicity. Thus, it is crucial to develop favorable growth hormone delivery systems to improve patient compliance. In the present study, to increase the oral bioavailability of growth hormone and improve patient compliance, enteric-coated capsules filled with monomethoxyl poly(ethylene glycol)-b-poly(L-lactide-co-glycolide) nanoparticles were prepared to facilitate oral growth hormone delivery. The nanoparticles were less than 100 nm in size, exhibited narrow polydispersity indices < 0.3, and showed a zeta potential of −4.87 mV. The highest efficiency of growth hormone encapsulation achieved in this study was nearly 70%. An in vitro release experiment showed that adequate amounts of growth hormone were retained under simulated gastric conditions and significant amounts of growth hormone were released under simulated intestinal conditions. The bioavailability of encapsulated growth hormone relative to subcutaneously injected growth hormone in Sprague-Dawley rats was 11.06%. Thus, the use of poly(ethylene glycol)-b-poly(L-lactide-co-glycolide) nanoparticles yielded promising results, and these agents should be investigated further regarding their potential as an oral growth hormone delivery system in the future.

Download Full-text

Preparation and Characterization of Poly(ethylene glycol)ylated Human Growth Hormone Antagonist

ACS Symposium Series - Poly(ethylene glycol) ◽

10.1021/bk-1997-0680.ch012 ◽

1997 ◽

pp. 170-181 ◽

Cited By ~ 10

Author(s):

Kenneth Olson ◽

Richard Gehant ◽

Venkat Mukku ◽

Kathy O'Connell ◽

Brandon Tomlinson ◽

...

Keyword(s):

Growth Hormone ◽

Ethylene Glycol ◽

Human Growth Hormone ◽

Human Growth ◽

Poly Ethylene Glycol ◽

Poly Ethylene

Download Full-text

Sustained release of human growth hormone from in situ forming hydrogels using self-assembly of fluoroalkyl-ended poly(ethylene glycol)

Biomaterials ◽

10.1016/j.biomaterials.2005.01.042 ◽

2005 ◽

Vol 26 (25) ◽

pp. 5259-5266 ◽

Cited By ~ 57

Author(s):

Giyoong Tae ◽

Julia A. Kornfield ◽

Jeffrey A. Hubbell

Keyword(s):

Growth Hormone ◽

Ethylene Glycol ◽

Sustained Release ◽

Self Assembly ◽

Human Growth ◽

Poly Ethylene Glycol ◽

In Situ Forming ◽

Poly Ethylene ◽

In Situ Forming Hydrogels

Download Full-text

Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Amphiphilic Copolymers for Long-Acting Injectables: Synthesis, Non-Acylating Performance and In Vivo Degradation

Molecules ◽

10.3390/molecules26051438 ◽

2021 ◽

Vol 26 (5) ◽

pp. 1438

Author(s):

Silvio Curia ◽

Feifei Ng ◽

Marie-Emérentienne Cagnon ◽

Victor Nicoulin ◽

Adolfo Lopez-Noriega

Keyword(s):

Ethylene Glycol ◽

Ring Opening ◽

Gel Chromatography ◽

Amphiphilic Copolymers ◽

Trimethylene Carbonate ◽

Poly Ethylene Glycol ◽

Poly Ethylene ◽

Long Acting ◽

In Vivo Degradation

This article presents the evaluation of diblock and triblock poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) amphiphilic copolymers (PEG-PTMCs) as excipients for the formulation of long-acting injectables (LAIs). Copolymers were successfully synthesised through bulk ring-opening polymerisation. The concomitant formation of PTMC homopolymer could not be avoided irrespective of the catalyst amount, but the by-product could easily be removed by gel chromatography. Pure PEG-PTMCs undergo faster erosion in vivo than their corresponding homopolymer. Furthermore, these copolymers show outstanding stability compared to their polyester analogues when formulated with amine-containing reactive drugs, which makes them particularly suitable as LAIs for the sustained release of drugs susceptible to acylation.

Download Full-text

Reduced and S-carboxymethylated human growth hormone: a probe for diabetogenic action

AJP Endocrinology and Metabolism ◽

10.1152/ajpendo.1984.247.5.e639 ◽

1984 ◽

Vol 247 (5) ◽

pp. E639-E644

Author(s):

C. M. Cameron ◽

J. L. Kostyo ◽

J. A. Rillema ◽

S. E. Gennick

Keyword(s):

Growth Hormone ◽

Amino Acid ◽

Human Growth Hormone ◽

Human Growth ◽

Mouse Mammary Gland ◽

Amino Acid Incorporation ◽

Acid Incorporation ◽

Hypophysectomized Rats

The biological activity profile of reduced and S-carboxymethylated human growth hormone (RCM-hGH) was determined to establish its suitability for study of the diabetogenic property of hGH. RCM-hGH was found to have greatly attenuated in vivo growth-promoting activity in the 9-day weight-gain test in hypophysectomized rats (approximately 1%) and to have a similar low order of in vitro activity in stimulating amino acid incorporation into the protein of the isolated rat diaphragm. RCM-hGH also only had approximately 1% of the in vitro insulin-like activity of the native hormone on isolated adipose tissue from hypophysectomized rats. In contrast, RCM-hGH retained substantial in vivo diabetogenic activity in the ob/ob mouse, appearing to have approximately 50% of the activity of the native hormone. RCM-hGH was also found to retain significant, although attenuated (25%), in vitro lactogenic activity when tested for the ability to stimulate amino acid incorporation into a casein-rich protein fraction in mouse mammary gland explants. Because RCM-hGH exhibits a high degree of diabetogenic activity, although lacking significant anabolic or insulin-like activities, it will be useful as a "monovalent" probe for the study of the molecular mechanism of the diabetogenic action of GH.

Download Full-text